Pfizer (PFE) Competitors

Pfizer (NYSE:PFE) and Amgen (NASDAQ:AMGN) are both large-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, earnings, media sentiment, risk, institutional ownership, valuation and profitability.

Do insiders and institutionals believe in PFE or AMGN?

68.4% of Pfizer shares are owned by institutional investors. Comparatively, 76.5% of Amgen shares are owned by institutional investors. 0.1% of Pfizer shares are owned by company insiders. Comparatively, 0.8% of Amgen shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Does the media refer more to PFE or AMGN?

In the previous week, Pfizer had 19 more articles in the media than Amgen. MarketBeat recorded 63 mentions for Pfizer and 44 mentions for Amgen. Amgen's average media sentiment score of 1.27 beat Pfizer's score of 1.27 indicating that Amgen is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pfizer	48 Very Positive mention(s)	4 Positive mention(s)	7 Neutral mention(s)	2 Negative mention(s)	2 Very Negative mention(s)	Positive
Amgen	37 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Is PFE or AMGN a better dividend stock?

Pfizer pays an annual dividend of $1.72 per share and has a dividend yield of 6.7%. Amgen pays an annual dividend of $9.52 per share and has a dividend yield of 3.2%. Pfizer pays out 91.5% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Amgen pays out 77.8% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Pfizer has increased its dividend for 16 consecutive years and Amgen has increased its dividend for 14 consecutive years. Pfizer is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Which has more volatility & risk, PFE or AMGN?

Pfizer has a beta of 0.52, suggesting that its share price is 48% less volatile than the S&P 500. Comparatively, Amgen has a beta of 0.49, suggesting that its share price is 51% less volatile than the S&P 500.

Do analysts recommend PFE or AMGN?

Pfizer presently has a consensus price target of $28.12, indicating a potential upside of 8.88%. Amgen has a consensus price target of $303.76, indicating a potential upside of 3.42%. Given Pfizer's stronger consensus rating and higher possible upside, equities research analysts clearly believe Pfizer is more favorable than Amgen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pfizer	1 Sell rating(s)	11 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	2.39
Amgen	2 Sell rating(s)	11 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.33

Is PFE or AMGN more profitable?

Amgen has a net margin of 18.96% compared to Pfizer's net margin of 16.84%. Amgen's return on equity of 174.71% beat Pfizer's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pfizer	16.84%	21.42%	9.12%
Amgen	18.96%	174.71%	13.12%

Which has stronger earnings & valuation, PFE or AMGN?

Pfizer has higher revenue and earnings than Amgen. Pfizer is trading at a lower price-to-earnings ratio than Amgen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pfizer	$63.63B	2.31	$8.03B	$1.88	13.74
Amgen	$33.42B	4.73	$4.09B	$12.23	24.02

Summary

Amgen beats Pfizer on 11 of the 20 factors compared between the two stocks.